Forty Seven, Inc. to Present Updated Data from Ongoing Phase 1b/2 Clinical Trial of 5F9 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma at 24th Congress of the European Hematology Association
In an additional oral presentation, Forty Seven will present initial data from its Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). These data in AML and MDS will have been previously presented in a poster session on
Details on the presentations are as follows:
Presentation Title: The first-in-class anti-CD47 antibody HU5F9-G4 with rituximab induces durable responses in relapsed/refractory DLBCL and indolent lymphoma: interim phase 1b/2 results
Oral Session Title: Aggressive Lymphomas – New Agents
Presentation Date & Time:
Abstract Code: S867
Location: Hall 5
Presentation Title: The first-in-class anti-CD47 antibody HU5F9-G4 is active and well tolerated alone or in combination with azacitidine in AML and MDS patients: initial phase 1b results
Oral Session Title: New Therapies in AML
Presentation Date & Time:
Abstract Code: S878
Location: Elicium 2
The accepted abstracts are now available online on the EHA website: https://ehaweb.org/congress/eha24/key-information/.
About
For more information please visit www.fortyseveninc.com or contact info@fortyseveninc.com.
For journalist enquiries please contact
For investor enquiries please contact
Source: Forty Seven, Inc.